Product
Vatiquinone
Aliases
EPI-743, PTC743
5 clinical trials
9 indications
Indication
Friedreich AtaxiaIndication
Mitochondrial DiseasesIndication
Drug-Resistant EpilepsyIndication
Leigh DiseaseIndication
Leigh syndromeIndication
Pontocerebellar Hypoplasia Type 6 (PCH6)Indication
Alpers DiseaseIndication
Mitochondrial DiseaseClinical trial
A Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich Ataxia (MOVE-FA)Status: Completed, Estimated PCD: 2023-04-04
Clinical trial
An Open-Label Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Vatiquinone in Children With Friedreich Ataxia Younger Than 7 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2024-10-05
Clinical trial
Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory EpilepsyStatus: Completed, Estimated PCD: 2023-03-18
Clinical trial
An Open-Label, Safety Study for Previously Treated Vatiquinone (PTC743) Subjects With Inherited Mitochondrial DiseaseStatus: , Estimated PCD: 2025-03-31
Clinical trial
Long-Term Open-Label Study to Assess the Safety and Efficacy of Vatiquinone in Patients With Friedreich AtaxiaStatus: , Estimated PCD: 2027-12-31